Directorio

We are doing this study to find out if a study drug called sacituzumab govitecan can improve outcomes for patients with high risk, early triple negative breast cancer (TNBC). We want to know if giving this drug in combination with pembrolizumab will work better than pembrolizumab on its own or better than pembrolizumab + capecitabine.

This study begins with about one month of screening tests, such as blood tests and exams, to see if a person can join. If eligible, people will be placed into one of two groups by chance. One group will receive a medicine called lisaftoclax with another medicine called azacitidine. The other group will receive a placebo, which has no active medicine, along with azacitidine. Treatment happens in cycles that last 28 days. During each cycle, lisaftoclax or placebo is taken by mouth for 14 days, and azacitidine is given by a shot or through a vein for 7 days. At the start, there will be more clinic visits, and visits may become less frequent over time. Participants will continue treatment as long as it is helping and side effects are manageable. After stopping treatment, there will be a follow up visit to check safety.

We are doing this study to find out if an experimental drug called asciminib (the study drug) is a safe and effective option for people with metastatic HER2+ breast cancer with brain metastases when it is combined with trastuzumab.

We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people who have pancreatic cancer that can be treated with surgery. We want to know if the study drug has a benefit when it is taken by patients before their surgery who then have standard chemotherapy after their surgery.

We are doing this study to compare 2 different options for preventing strokes for people who have atrial fibrillation. We want to find out if apixaban or aspirin is the better choice to help prevent future strokes for patients with atrial fibrillation and who had a recent brain hemorrhage.

If you join this study, you will receive a medicine called ASP546C through a vein every three weeks. You will also give blood and urine samples so doctors can check your health and how your body responds to the treatment. During the study, you will have regular scans such as CT or MRI to see how your cancer is changing.

This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.